pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Pain · news · pharmadog
← back to Pain
News · Pain
143
stories
10d
BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOs
biospace
11d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
11d
Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles
fda recalls
12d
Taylor Fresh Foods Recalls Products Made with Jalapeno Peppers Because of Possible Health Risk
fda recalls
12d
NatureBest Precut & Produce LLC Voluntarily Recalls Products Containing Jalapenos Due to Potential Salmonella Contamination
fda recalls
13d
Lexunder Inc Recalls Food to Live Brand Green Powder Products Because of Possible Health Risk
fda recalls
13d
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
14d
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
fiercebiotech
14d
Updated: BlossomHill, Latigo cap four-IPO week with combined $496M haul
endpoints
14d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
FDA approves Moderna’s mRNA flu vaccine
biopharma dive
15d
Opinion: STAT+: Stop asking if AI is good for medicine
stat
15d
Cardiac drug developer Braveheart banks more than $382M in IPO
biopharma dive
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
16d
Opinion: Tear down the wall between M.D. and D.O. education
stat
16d
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
fda medwatch
17d
Opinion: How Josée became one of the 7.9% of Québécois who die by assisted suicide
stat
17d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
17d
STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
stat
17d
STAT+: Is there a pharma mega-merger in the making?
stat
17d
Boticelli Foods Recalls Bettergoods Pistachio Nut Butter Because of Possible Health Risk
fda recalls
17d
STAT+: BioNTech names Guido Oelkers its new CEO
stat
18d
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Lidocaine Hydrochloride and Bupivacaine Hydrochloride in Dextrose Injection
fda medwatch
18d
American Regent, Inc. Animal Health Issues Nationwide Recall of Two Lots of Adequan® Canine and Two Lots of Adequan® I.M. Due to Visible Glass Fiber Material in the Product
fda medwatch
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
21d
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
endpoints
22d
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
← prev
page 2 of 5
next →
